WEKO3
アイテム
Whole-Body Distribution and Brain Tumor Imaging with 11C-4DST: a Pilot Study
https://repo.qst.go.jp/records/46149
https://repo.qst.go.jp/records/4614945a23a60-7ce1-46e8-b90d-9ef787adb449
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2011-07-25 | |||||
| タイトル | ||||||
| タイトル | Whole-Body Distribution and Brain Tumor Imaging with 11C-4DST: a Pilot Study | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Toyohara, Jun
× Toyohara, Jun× Nariai, Tadashi× Sakata, Muneyuki× Oda, Keiichi× Ishii, Kenji× Irie, Toshiaki× Saga, Tsuneo× Kubota, Kazuo× Ishiwata, Kiichi× 豊原 潤× 成相 直× 入江 俊章× 佐賀 恒夫 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Recently, we developed [methyl-11C]4'-thiothymidine (11C-4DST) as an in vivo cell proliferation marker. The present study was performed to determine the safety, distribution, radiation dosimetry, and initial brain tumor imaging of 11C-4DST in humans. Methods: Multiorgan biodistribution and radiation dosimetry of 11C-4DST were assessed in 3 healthy humans, who underwent 2-h whole-body PET scanning. Radiation dosimetry was estimated from the residence times of source organs using the OLINDA program. Six brain tumor patients underwent dynamic 11C-4DST scans with arterial blood sampling. These patients were also evaluated with 11C-methionine PET on the same day (n = 4) as, or 3 wk before (n = 2), 11C-4DST PET studies. Metabolites in plasma and urine samples were analyzed by high-performance liquid chromatography. Breakdown of the blood–brain barrier in tumor tissue was confirmed by gadolinium-enhanced T1-weighted MRI. Results: There were no serious adverse events in any subjects at any time during the study period. 11C-4DST PET demonstrated selective uptake in the bone marrow, which has a high rate of proliferation. In addition, high-level uptake was also seen in the liver. The highest absorbed organ dose was in the urinary bladder wall (17.6 muGy/MBq). The estimated effective dose for 11C-4DST was 4.2 muSv/MBq. 11C-4DST showed little uptake in normal brain tissues, resulting in low background activity for imaging of brain tumors. In contrast, 11C-4DST PET demonstrated rapid uptake in aggressive tumor masses, whereas no signal of 11C-4DST was seen in clinically stable disease in which 11C-methionine uptake was high. The distribution pattern of 11C-methionine in tumor regions was not always identical to that of 11C-4DST. Analysis of plasma samples by high-performance liquid chromatography indicated that more than 60% of the radioactivity was present as unchanged 11C-4DST at 20 min. Conclusion: The initial findings of the present study in a small group of patients indicated that 11C-4DST PET is feasible for imaging of brain tumors. Dosimetry and pharmacologic safety were acceptable at the dose required for adequate PET images. | |||||
| 書誌情報 |
Journal of Nuclear Medicine 巻 52, 号 8, p. 1322-1328, 発行日 2011-08 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 0161-5505 | |||||
